432 results
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
-term efficacy & safety data GPRC5D CAR T in RRMM & golcadomide in NHL in registrational trials Business Development Q1 2024 Performance *See “Forward … % improvement in PANSS Differentiated safety: Continued lack of weight gain, metabolic dysfunction, & extrapyramidal symptoms Differentiated profile supported
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
of clinical remission at Week 12. The safety profile of Zeposia in this study was consistent with that observed in previously reported trials.
Zeposia
Data … from the Phase 3 DAYBREAK open-label extension trial demonstrated the long-term efficacy and safety profile of Zeposia in patients with relapsing forms
8-K
EX-99.1
dvf46 lwo3
18 Mar 24
Strengthening Neuroscience Portfolio
8:56am
424B5
kvlsubyo r7v
16 Feb 24
Prospectus supplement for primary offering
4:34pm
424B2
w3ol6teowh84c7
13 Feb 24
Prospectus for primary offering
8:00am
8-K
EX-99.1
gm88op
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
SC TO-T
EX-99
nf9khd9z8r7skrv7
25 Jan 24
Third party tender offer statement
8:13am
8-K
EX-99.1
o8cfv rqr00
8 Jan 24
Regulation FD Disclosure
10:29am
DFAN14A
fv8hi7
22 Dec 23
Additional proxy materials by non-management
4:36pm